Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Alpelisib Plus Fulvestrant or Letrozole Demonstrates Sustained Benefits Across Subgroups of Patients with PIK3CA-Mutated HR+/HER2- Advanced Breast Cancer.
Journal: The oncologist
Published: March 29, 2022
Benefits of Adjuvant Chemotherapy Differ by Menopausal Status in Women with HR+/HER2- Early Breast Cancer, 1-3 Positive Nodes, and a Low Recurrence Score.
Journal: The oncologist
Published: March 29, 2022
SABCS 2021 Insights on Breast Cancer Research: An Interview with Dr. Laura Spring.
Journal: The oncologist
Published: March 29, 2022
Pyrotinib Improves Survival in Previously Treated HER2-Positive Metastatic Breast Cancer.
Journal: The oncologist
Published: March 29, 2022
Early Switch to Fulvestrant Plus Palbociclib Improves Outcomes in ESR1-Mutated, Estrogen Receptor-Positive Metastatic Breast Cancer.
Journal: The oncologist
Published: March 29, 2022
Elacestrant Improves Progression-Free Survival After Endocrine Therapy for Estrogen Receptor-Positive Metastatic Breast Cancer.
Journal: The oncologist
Published: March 29, 2022
Trastuzumab Deruxtecan Improves Progression-Free Survival and Intracranial Response in Patients with HER2-Positive Metastatic Breast Cancer and Brain Metastases.
Journal: The oncologist
Published: March 29, 2022
Showing 1-9 of 9
Last Updated: 09/26/2026